A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat

Protective Effects of a Coumarin Derivative in Diabetic Rats

“…18 Cloricromene protects rats from lipopolysaccharide (LPS)-induced endotoxemia by blocking NF-B activation, leading to inhibition of NO and TNF␣ overproduction, 26 reversing the LPS-induced vascular hyporeactivity. Since cloricromene influences TNF␣ production, the drug has recently been evaluated in an animal model of inflammatory bowel disease, 27 where TNF␣ has a key role; cloricromene significantly reduced tissue concentrations of TNF␣ and myeloperoxidase activity, whereas no effect was seen on blood coagulation parameters. 27 Corsini and colleagues 28 showed that cloricromene inhibits LPS-induced transcription of TNF␣ and activation of NF-B by interfering with LPS-induced cellular oxidative activity.…”

“…Since cloricromene influences TNF␣ production, the drug has recently been evaluated in an animal model of inflammatory bowel disease, 27 where TNF␣ has a key role; cloricromene significantly reduced tissue concentrations of TNF␣ and myeloperoxidase activity, whereas no effect was seen on blood coagulation parameters. 27 Corsini and colleagues 28 showed that cloricromene inhibits LPS-induced transcription of TNF␣ and activation of NF-B by interfering with LPS-induced cellular oxidative activity. These results 28 demonstrated that cloricromene interferes with the early signal transduction pathway triggered by LPS.…”

Cloricromene effect on the enzyme activities of the tryptophan–nicotinic acid pathway in diabetic/hyperlipidemic rabbits

“…Cloricromene has been also found to protect rats from lipopolysaccharide-induced endotoxemia by blocking nuclear factor-nB activation, leading to inhibition of NO and TNF-a overproduction (Ianaro et al, 2004), reversing the lipopolysaccharide-induced vascular hyporeactivity. Since cloricromene influences TNF-a production, the drug has been recently evaluated on an animal model of inflammatory bowel disease (Fries et al, 2004), where TNF-a has a key role; the drug significantly reduced the tissue concentrations of TNF-a and myeloperoxidase activity, whereas no effect was seen on blood coagulation parameters (Fries et al, 2004). In addition, cloricromene is able to influence the release of endothelin-1 in patients with peripheral atherosclerotic arteriopathies (Saitta et al, 1996) and it possesses a notable inhibitory effect on polymorphonuclear neutrophil function (Groban et al, 1998;Zatta and Bevilacqua, 1999).…”